ClinicalTrials.gg
Active, not recruitingNCT07165743Updated Sep 10, 2025

Evaluation of Fetal Bladder Emptying During the 11-14 Weeks' Ultrasound Examination as a Negative Predictive Marker for Chromosomal Abnormalities

An observational study in Chromosomal Aneuploidies (e.g., Trisomy 21, Trisomy 18, Trisomy 13); Prenatal Screening Accuracy, sponsored by Haseki Training and Research Hospital. Active, not recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-10.

Sponsored by Haseki Training and Research Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
270
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 19 studies in Down Syndrome with a site in Turkey — 1 open to participants now, 2 under way, none of them phase 3. Down Syndrome · Turkey.

Started
2025
with 2 others
Observational
6 of 19
none open now
Registered
16th of 19
by date
Lead sponsor
1 of 19
Haseki Training and Research Hospital

Among the 19 studies in Down Syndrome with a site in Turkey, this one is one of 3 that started in 2025, is one of 6 observational ones, and was the 16th registered.

Down Syndrome

439 studies on the registry are indexed under Down Syndrome; 99 are open to participants now.

Browse Down Syndrome studies →

Open to participants now

1 of the 19 studies in Down Syndrome with a site in Turkey is open now. Recruiting first, the newest first:

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 74 Down Syndrome studies recruiting now, 14 (19%) set no upper age limit and 57 (77%) stop at 75 or younger; 60 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Down Syndrome with a site in Turkey, or all of them as a file.
02

Study summary

Template-Based Brief Summary (Sağlık Profesyonelleri İçin)

Study Title:

The Negative Predictive Value of First-Trimester Fetal Bladder "Rapid Emptying" (≤40 minutes and post-void ≤2 mm) for Major Chromosomal Aneuploidies: A Prospective Diagnostic Accuracy Study.

Purpose:

To evaluate whether the dynamic phenotype of rapid bladder emptying at 11-14 weeks reduces the likelihood of major chromosomal abnormalities (particularly Trisomy 21) compared to fetuses without this phenotype.

Design:

Single-center, prospective observational cohort.

Population:

270 singleton pregnancies between 11+0 and 14+0 weeks.

Procedures:

Real-time sagittal ultrasound observation for 40 minutes.

Documentation of bladder emptying time and post-void longitudinal bladder diameter.

Concurrent measurement of CRL, NT, ductus venosus waveform.

Gold standard confirmation with cfDNA or invasive karyotyping in high-risk cases.

Primary Endpoint:

Negative predictive value (NPV), ROC-AUC, sensitivity/specificity for aneuploidy detection.

Secondary Endpoints:

Rate of invasive testing, performance in combined models with cfDNA and biophysical markers, Net Reclassification Index.

Duration:

5 months (08/2025 - 01/2026).

Potential Impact:

If validated, the rapid emptying phenotype may serve as a low-risk marker, reduce unnecessary invasive procedures, and refine first-trimester screening algorithms.

03

Conditions studied

  • Chromosomal Aneuploidies (e.g., Trisomy 21, Trisomy 18, Trisomy 13); Prenatal Screening Accuracy

Keywords

  • First-trimester screening Chromosomal abnormalities Prenatal diagnosis Ultrasound Negative predictive value (NPV) Fetal bladder
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Prospective cohort of 270 consecutive healthy pregnant women with singleton fetuses, attending first-trimester screening (11 - 14 GA) at a tertiary perinatology center in Istanbul, Türkiye.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Singleton, viable pregnancy between 11 + 0 and 14 + 0 gestational weeks (GA)
  • Maternal age 18 - 45 years at enrollment
  • Able to provide written

Exclusion criteria

Exclusion Criteria:

  • Multiple gestation (twins, higher order)
  • Major fetal structural anomaly detected at index scan
  • Known serious maternal comorbidity (e.g., insulin-dependent diabetes, uncontrolled hypertension, renal or disease)
  • Participation in another interventional research study during the current pregnancy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
270 participants (estimated)
Target follow-up
270 Months
Patient registry
Yes

Groups and cohorts

  • Pregnancies in which the fetal bladder empties completely within ≤ 40 minutes

    Diagnostic Test: 40-Minute Real-Time First-Trimester Ultrasonography

  • Pregnancies in which the bladder does not meet the rapid-emptying criteria

    Diagnostic Test: 40-Minute Real-Time First-Trimester Ultrasonography

Interventions

  • Diagnostic test40-Minute Real-Time First-Trimester Ultrasonography

    A one-time midsagittal ultrasound performed between 11 +0 and 14 +0 weeks. Bladder emptying time and post-void longitudinal bladder diameter are recorded. No invasive procedures are performed.

06

What researchers measure

Primary outcomes

  1. Negative Predictive Value (NPV) of Rapid Fetal Bladder Emptying for Detecting Major Chromosomal Aneuploidy

    Proportion of fetuses with the rapid-emptying phenotype (≤ 40-minute complete emptying + post-void longitudinal bladder diameter ≤ 2 mm) who are subsequently confirmed not to have a major chromosomal aneuploidy (Trisomy 21, 18, or 13) by cfDNA, invasive karyotype, or postnatal testing.

    Time frame: From enrollment at 11 + 0 to 14 + 0 gestational weeks until definitive genetic result or delivery, whichever comes first (≈ 26 weeks).

07

Study locations

1 site
  • SBÜ Haseki Training and Research Hospital - Perinatology Department
    Istanbul, Istanbul (Sultangazi District) 34265, Turkey (Türkiye)
08

References and documents

Publications

  • Arasaratnam M, Balakrishnar B, Crumbaker M, Turner S, Hayden AJ, Brooks A, Patel MI, Lau H, Woo H, Bariol S, Gurney H. Patterns of care and outcomes of men with germ cell tumors in a high-volume Australian center. Asia Pac J Clin Oncol. 2022 Apr;18(2):e23-e31. doi: 10.1111/ajco.13548. Epub 2021 Jun 21. PubMed 34152083 ↗
  • Muller K, Kufner K, Prange K, Bengel J. [Screening for Anxiety in People with an Intellectual Disability: German Version of the "Glasgow Anxiety Scale for People with an Intellectual Disability" (GAS-ID)]. Psychiatr Prax. 2019 Jul;46(5):274-280. doi: 10.1055/a-0843-3373. Epub 2019 Mar 19. German. PubMed 30891726 ↗
  • Zhu R, Lv W, Sun C, Qin C, Zhang D, Long Z. A facile strategy to fabricate high-barrier, water- and oil-repellent paper with carboxymethyl cellulose/collagen fiber/modified polyvinyl alcohol. Carbohydr Polym. 2023 Aug 15;314:120933. doi: 10.1016/j.carbpol.2023.120933. Epub 2023 Apr 20. PubMed 37173031 ↗
  • Savarese JJ, Tabler NG Jr. Multimodal analgesia as an alternative to the risks of opioid monotherapy in surgical pain management. J Healthc Risk Manag. 2017 Jul;37(1):24-30. doi: 10.1002/jhrm.21262. PubMed 28719091 ↗
  • Chasserant P, Gosgnach M. Improvement of peri-operative patient management to enable outpatient colectomy. J Visc Surg. 2016 Nov;153(5):333-337. doi: 10.1016/j.jviscsurg.2016.07.006. Epub 2016 Sep 23. PubMed 27671006 ↗
  • Capone V, Persico N, Berrettini A, Decramer S, De Marco EA, De Palma D, Familiari A, Feitz W, Herthelius M, Kazlauskas V, Liebau M, Manzoni G, Maternik M, Mosiello G, Schanstra JP, Vande Walle J, Wuhl E, Ylinen E, Zurowska A, Schaefer F, Montini G. Definition, diagnosis and management of fetal lower urinary tract obstruction: consensus of the ERKNet CAKUT-Obstructive Uropathy Work Group. Nat Rev Urol. 2022 May;19(5):295-303. doi: 10.1038/s41585-022-00563-8. Epub 2022 Feb 8. PubMed 35136187 ↗
  • Lesieur E, Barrois M, Bourdon M, Blanc J, Loeuillet L, Delteil C, Torrents J, Bretelle F, Grange G, Tsatsaris V, Anselem O. Megacystis in the first trimester of pregnancy: Prognostic factors and perinatal outcomes. PLoS One. 2021 Sep 7;16(9):e0255890. doi: 10.1371/journal.pone.0255890. eCollection 2021. PubMed 34492029 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) underlying the primary and secondary outcome analyses-including fetal bladder emptying time, post-void longitudinal bladder diameter, nuchal translucency, ductus venosus waveform, cfDNA results, and karyotype confirmation-will be shared with qualified researchers upon reasonable request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: De-identified IPD, çalışma protokolü, SAP ve boş ICF; ana sonuçların hakemli dergide yayımlanmasından itibaren 12 ay içinde erişime açılacak ve 5 yıl süreyle paylaşılabilir olacaktır (yaklaşık Temmuz 2027 - Temmuz 2032).

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Oct 2025, 2 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2025
First posted
Sep 10, 2025
StartActual
Aug 28, 2025
Primary completionEst.
Oct 31, 2025
CompletionEst.
Jan 30, 2026
Last update
Sep 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07165743
Lead sponsor
Haseki Training and Research Hospital
Responsible party
Can Bilginer (Fellow at Perinatology department, Haseki Training and Research Hospital) — Principal investigator
First posted
Sep 10, 2025
Start date
Aug 28, 2025
Primary completion
Oct 31, 2025 (estimated)
Completion
Jan 30, 2026 (estimated)
Last update
Sep 10, 2025
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion